| Miss Lindsey Taylor Hood, MS CCC-SLP | |
|
770 W Rock Creek Rd Ste 109, Norman, OK 73069-8580 | |
| (918) 931-2867 | |
| Not Available |
| Full Name | Miss Lindsey Taylor Hood |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 770 W Rock Creek Rd Ste 109, Norman, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063033272 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | CF130 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Lindsey Taylor Hood, MS CCC-SLP 801 Nw 10th St Apt 122, Oklahoma City, OK 73106-6904 Ph: (918) 931-2867 | Miss Lindsey Taylor Hood, MS CCC-SLP 770 W Rock Creek Rd Ste 109, Norman, OK 73069-8580 Ph: (918) 931-2867 |
News Archive
Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.
One of the most important tasks of the immune system is to identify what is foreign and what is self. If this distinction fails, then the body's own structures will be attacked, the result of which could be an autoimmune disease such as diabetes mellitus type 1 or multiple sclerosis. The only way to protect against these afflictions is to destroy all immune factors that turn against the body's own tissue - in other words: immune tolerance.
A simple 7-item screening tool can help clinicians identify patients at risk for chronic obstructive pulmonary disease (COPD), even if they are not experiencing any symptoms.
The Lancet Oncology has published results from the largest ever trial of a single melanoma treatment. The open label safety study was conducted to assess the tolerability of Zelboraf (vemurafenib), and featured 3,222 patients from across 44 countries.1 246 of these patients were from the UK.
MAXIMUS, a leading provider of government services worldwide, announced today that four of its customer contact centers have been recognized as "Certified Centers of Excellence" by BenchmarkPortal.
› Verified 5 days ago
Suzanne Smith Brasher, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 410 Litchfield Ln, Norman, OK 73072 Phone: 405-364-6191 | |
Mrs. Bailey Elilzabeth Holzhausen, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: Pediatric Communication Solutions, 2761 Washington Drive Suite 111, Norman, OK 73069 Phone: 405-438-0090 Fax: 405-493-0717 | |
Hannah Pierce, M.S., CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 2002 E Robinson St, Norman, OK 73071 Phone: 405-307-2800 | |
Tammie Christian, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 250 12th Ave Ne, Norman, OK 73071 Phone: 405-579-2275 | |
Mrs. Laura Kalajdzic, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1223 Country Club Dr, Norman, OK 73072 Phone: 405-212-7209 | |
Aubrey Danser, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2429 Westport Dr, Norman, OK 73069 Phone: 405-308-9120 Fax: 405-928-5530 |